EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology

Stéfanie Parisien-La Salle, Jenifer M Brown, Sanan Mahrokhian, Isabelle Hanna, Brooke Honzel, Laura C Tsai, Andrew J Newman, Thomas J Wang, Anand Vaidya iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf129 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Stéfanie Parisien-La Salle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston,…. Hauptthemen laut MEDLINE: Hyperaldosteronism, Aldosterone, Natriuretic Peptide, Brain, Angiotensin II. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, American Heart Association Career Development Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

A continuum of non-suppressible aldosterone production has been demonstrated in normotensive individuals, termed subclinical primary aldosteronism (PA), and is consistently associated with increased risk for developing hypertension and cardiovascular disease. The hormonal mechanisms accounting for subclinical PA are not well understood.

Methods

To quantify the magnitude of subclinical PA, prospectively recruited normotensive participants (n = 75) had their maximally suppressed plasma aldosterone assessed after maintaining supine posture following an oral sodium loading protocol. To investigate the endocrine mechanisms involved with this continuum, multiple maneuvers were conducted to evaluate: (i) natriuretic peptide physiology (N-terminal pro B-type natriuretic peptide [NT-proBNP] suppression and stimulation using dietary sodium modulation); (ii) angiotensin II (AngII)-dependent aldosterone production (via dietary sodium restriction and via infusion of exogenous AngII); (iii) AngII-independent aldosterone production (via saline suppression test [SST]); and (iv) ACTH-mediated aldosterone production (via dexamethasone suppression test and ACTH-stimulation test).

Results

Greater magnitude of subclinical PA was associated with lower basal NT-proBNP (P-trend < .01) and blunted stimulation of NT-proBNP following sodium loading (P-trend = .023). The magnitude of subclinical PA was also associated with greater AngII-dependent (P-trend < .001) and AngII-independent (P-trend < .001) aldosterone production and paralleled the severity of ACTH-mediated aldosterone production (P-trends < .001). Following SST, 24.2% of participants had a post-saline aldosterone greater than 10 ng/dL and 72.7% had a post-saline aldosterone greater than 6 ng/dL, confirming that the continuum of subclinical PA included overt PA pathophysiology within these normotensive participants.

Conclusion

These findings demonstrate that the pathophysiologic continuum of subclinical PA in normotensive people is characterized by natriuretic peptide insufficiency and heightened aldosterone responses to both AngII and ACTH. These early maladaptive hormonal changes provide mechanistic explanations for the role of subclinical PA in the pathogenesis of hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismAldosteroneNatriuretic Peptide, BrainAngiotensin IIAdrenocorticotropic HormoneAsymptomatic DiseasesProspective StudiesBlood PressurePeptide FragmentsSodium, DietaryDiet, Sodium-RestrictedDexamethasoneLongitudinal StudiesDiagnostic Techniques, EndocrineAdrenal GlandsHumansMaleFemaleAdultMiddle AgedAged

Stichwörter der Autor:innen

ACTHAngiotensin IINT-proBNPaldosteroneprimary aldosteronism

Substanzen

Aldosteronepro-brain natriuretic peptide (1-76)Peptide FragmentsNatriuretic Peptide, BrainAngiotensin IIAdrenocorticotropic HormoneSodium, DietaryDexamethasone

Autor:innen und Institutionen

  • Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Anand Vaidya

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • American Heart Association Career Development Award
  • National Institutes of Health/National Heart, Lung, and Blood Institute
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Parisien-La Salle, S., Brown, J. M., Mahrokhian, S., Hanna, I., Honzel, B., Tsai, L. C., Newman, A. J., Wang, T. J., & Vaidya, A. (2025). Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf129

Vancouver

Parisien-La Salle S, Brown JM, Mahrokhian S, Hanna I, Honzel B, Tsai LC, et al. Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf129

BibTeX
@article{ParisienLaSalle2025,
  author = {Parisien-La Salle, Stéfanie and Brown, Jenifer M and Mahrokhian, Sanan and Hanna, Isabelle and Honzel, Brooke and Tsai, Laura C and Newman, Andrew J and Wang, Thomas J and Vaidya, Anand},
  title = {Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf129}
}
Kostenlos starten →